immuno oncology compound library

A unique collection of 449 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening；

Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 3188 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1702 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study；

A unique collection of 334 nucleoside and nucleotide analogues, can be used for research and development of anti-viral, anti-tumor, anti-fungal, and anti-depressive drugs;

1066 types of active small molecules associated with pyroptosis for high-throughput and high-content screening.

791 peptides can be used in peptide drug development and signaling transduction and mechanism study;

A collection of 950 natural product molecules originated from Mongolian medicine, which can be used for high-throughput and high-content screening.

A unique collection of 1147 monomers from 60 TCM plants, a powerful tool for anti-COVID-19 drug discovery, can be used for HTS and HCS screening；

A unique collection of 1040 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;

A unique collection of 2540 compounds targeting CNS signaling for high throughput screening (HTS) and high content screening (HCS) for new drugs;

It is well-selected from Bioactive compound library Plus (D7800), from which 1-15 compounds with the highest scores (activity value, pharmacological properties, structure-diversity, etc.) were chosen. This library consists of 989 compounds without compro

A unique collection of 492 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 677 cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 7234 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 904 antibacterial bioactive compounds, a powerful tool for antibacterial drug development;

A unique collection of 812 promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

A unique collection of 1197 stem cell differentiation signaling targeted compounds for high throughput and high content screening;

A unique collection of 2247 anti-obesity compounds for high throughput and high content screening;

A collection of 17100 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

A unique collection of 1283 endogenous metabolism-related compounds for research in endogenous metabolism-related diseases and drug screening.

A unique collection of 1940 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of 683 diabetes related compounds;

A unique collection of 1513 neurotransmitter receptor compounds, can be used for HTS and HCS screening；

A unique collection of 1408 cardiovascular diseases related compounds for high throughput screening (HTS) and high content screening (HCS);

A collection of 747 natural product molecules originated from Tibetan medicine, which can be used for high-throughput and high-content screening.

A unique collection of 3404 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 910 DNA Damage & Repair related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1544 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 4630 approved and clinical drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2427 of orally active compounds for high-throughput screening and high-content screening.

A unique collection of 1268 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);

Well-chosen 1468 anti-tumor compounds with unique structures;

Well-chosen 695 compounds with unique structures targeting transcription factor;

A unique collection of 1133 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents；

A unique collection of 2320 metabolic pathway-related bioactive small molecule compounds for high-throughput, high-content screening.

A unique collection of 153 compounds targeting histaminergic receptor and melatonin receptor for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 2154 compounds related to neurodegenerative diseases can be used for HTS or HCS；

A unique collection of 210 ubiquitination related small chemicals can be used for high throughput and high content screening；

TargetMol’s Cuproptosis Compound Library is a collection of 400 compounds related to copper-dependent death that can be used to study its mechanism and related diseases.

A unique collection of 1180 potential anti-fibrosis compounds, can be used in HTS and HCS;

1163 compounds associated with depression that can be used for high-throughput and high-content screening

76 exosome-related compounds that can be used for high-throughput and high-content screening.

80 well-chosen unique AMPK-targeted small molecules；

A unique collection of 2545 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 4720 anti-inflammation compounds effective for high throughput screening and high content screening.

A unique collection of 3048 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high throughput screening (HTS) and high content screening (HCS);

678 hypertension-related small molecules for high-throughput and high-content screening.

A unique collection of 262 toxic substances for high throughput screening (HTS) and high content screening (HCS);